TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9922777

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-mitomycin C regimen with radiotherapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-cisplatin regimen
Number of subjects: 2
Study: 1291521

Group type: EXPERIMENTAL
Intervention: 40% citric acid treatment to remove smear layer with Tubliseal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40% citric acid treatment to remove smear layer with Vitrebond
Number of subjects: 60

Group type: COMPARATOR
Intervention: Smear layer intact with Tubliseal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Smear layer intact with Vitrebond
Number of subjects: 60
Study: 6512869

Group type: EXPERIMENTAL
Intervention: Rational Emotive Therapy (RET)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 16
Study: 30796868

Group type: EXPERIMENTAL
Intervention: Biomechanical correction, DN, TrPs-pressure release
Number of subjects: 87

Group type: COMPARATOR
Intervention: Therapeutic exercises, DN, TrPs-pressure release
Number of subjects: 87
Study: 30099354

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 71
Study: 26834052

Group type: EXPERIMENTAL
Intervention: Tailored face-to-face counseling session, audio quit materials, printed quit materials, Quitline contact details
Number of subjects: 55

Group type: COMPARATOR
Intervention: Printed quit materials, Quitline contact details
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined annual point prevalence quit rate
Number of subjects: 55
Study: 24934783

Group type: EXPERIMENTAL
Intervention: Telephone-based lifestyle intervention (LI) including diet (500 to 1,000 kcal per day deficit) and physical activity (150 to 200 minutes of moderate-intensity physical activity per week) for 24 months
Number of subjects: 338

Group type: COMPARATOR
Intervention: Mail-based delivery of general health information alone
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Telephone-based lifestyle intervention (LI)
Number of subjects: 338
Study: 22710783

Group type: EXPERIMENTAL
Intervention: Electromagnetic-guided distal locking procedures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Free-hand fluoroscopic-guided distal locking procedures
Number of subjects: 100
Study: 19172250

Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-alcoholic drink (placebo)
Number of subjects: 96
Study: 17429726

Group type: EXPERIMENTAL
Intervention: Oral pantoprazole (80 mg BID for 3 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous pantoprazole (80 mg IV bolus and 8 mg/hr infusion for 3 days)
Number of subjects: 25
Study: 14767029

Group type: EXPERIMENTAL
Intervention: FTY (0.25-3.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FTY (0.25-2 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FTY (3.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FTY (0.25-2 mg) or (3.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FTY
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FTY (high-dose)
Number of subjects: 16
Study: 11436678

Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate (Mononit) 10 or 20 mg twice a day
Number of subjects: 13
Study: 9602958

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amlodipine (Control)
Number of subjects: 60
Study: 7625339

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Medium-fat diet (MF)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 7
Study: 2575572

Group type: EXPERIMENTAL
Intervention: Somatostatin administration for two days
Number of subjects: 54

Group type: COMPARATOR
Intervention: No somatostatin administration (Control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Somatostatin administration
Number of subjects: 54
Study: 31123

Group type: EXPERIMENTAL
Intervention: Laminar air flow group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Laminar air flow group (Aplastic anemia)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Aplastic anemia)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Laminar air flow group (Acute leukemia)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (Acute leukemia)
Number of subjects: 90
Study: 31238784

Group type: EXPERIMENTAL
Intervention: WeChat group intervention (70 patients with pre-hospital electrocardiography transmission via WeChat)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (70 patients without pre-hospital electrocardiography transmission)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: WeChat group intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 31237571

Group type: EXPERIMENTAL
Intervention: Needle-tip pressure measurement
Number of subjects: 400

Group type: COMPARATOR
Intervention: Fluoroscopy (FC)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional Loss of Resistance (LOR)
Number of subjects: 400
Study: 28591778

Group type: EXPERIMENTAL
Intervention: 2D_M0,6 (2-dose schedule at months 0 and 6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2D_M0,12 (2-dose schedule at months 0 and 12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3D_M0,1,6 (3-dose schedule at months 0, 1, and 6)
Number of subjects: 0
Study: 26114996

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with diabetes educators videoconferencing monthly to review glucose and blood pressure readings.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changing medication dose (as opposed to starting or stopping a medication).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjusting glucose-lowering agents compared with antihypertensive or antilipid medications.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher total Diabetes Symptom Checklist-Type 2 symptom severity score.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater number of glucose readings submitted by participants.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High score on surveys measuring impact of telemedicine on patient's knowledge, adherence, and satisfaction.
Number of subjects: 0
Study: 24096188

Group type: EXPERIMENTAL
Intervention: Tailored exercise training and diet counseling program
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care (no lifestyle intervention)
Number of subjects: 264
Study: 21640651

Group type: EXPERIMENTAL
Intervention: Clazosentan (5 mg/h)
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 19486720

Group type: COMPARATOR
Intervention: Drug-eluting stents
Number of subjects: 10727
Study: 16818012

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination neoadjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local therapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delay of cystectomy beyond 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate cystectomy with adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with monitoring of response
Number of subjects: 0
Study: 15373236

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 54

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 54
Study: 11050519

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.025 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.05 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 143
Study: 9029036

Group type: EXPERIMENTAL
Intervention: Glycosylated rG-CSF (lenograstim)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonglycosylated rG-CSF (filgrastim)
Number of subjects: 30
Study: 7879749

Group type: EXPERIMENTAL
Intervention: Injecting at friends' residence
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Injecting in shooting galleries
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Injecting in semipublic areas
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Frequency of injecting with others
Number of subjects: 630
Study: 2843255

Group type: EXPERIMENTAL
Intervention: Low-dose heparin + dihydroergotamine (A)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin + dihydroergotamine (B)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 356
Study: 31420748

Group type: COMPARATOR
Intervention: 2.5 mg IR on awakening QD
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: 25 mg DR following breakfast QM
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: 37.5 mg DR following breakfast QM
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: DR groups (25 mg and 37.5 mg)
Number of subjects: 565

Group type: COMPARATOR
Intervention: IR group
Number of subjects: 565
Study: 31201692

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (20 ml of 2.5% bupivacaine hydrochloride)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (0 ml of bupivacaine)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study: 28410453

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 20
Study: 24983707

Group type: EXPERIMENTAL
Intervention: Maintenance Counseling
Number of subjects: 130

Group type: COMPARATOR
Intervention: Contact Control
Number of subjects: 130
Study: 23741350

Group type: EXPERIMENTAL
Intervention: Naloxone (21 microg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22125893

Group type: EXPERIMENTAL
Intervention: Clinical hypnosis in addition to conventional medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical management without hypnosis
Number of subjects: 0
Study: 19672175

Group type: EXPERIMENTAL
Intervention: Ephedrine (8 mg/ml)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Phenylephrine (100 microg/ml)
Number of subjects: 104
Study: 16139450

Group type: EXPERIMENTAL
Intervention: Estrogen/hormone therapy (ET/HT) for 3 years
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Estrogen/hormone therapy (ET/HT)
Number of subjects: 489
Study: 15640848

Group type: EXPERIMENTAL
Intervention: Influenza split vaccine
Number of subjects: 876

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 876
Study: 11130166

Group type: EXPERIMENTAL
Intervention: Dorzolamide (two drops in one eye)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (two drops in the other eye)
Number of subjects: 35
Study: 9311511

Group type: EXPERIMENTAL
Intervention: Formoterol inhaled at high flow rate (120 L.min-1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol inhaled at low flow rate (60 L.min-1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8318319

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fentanyl 5 micrograms ml‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: combined group (0.125% bupivacaine with fentanyl 5 micrograms ml‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: bupivacaine group
Number of subjects: 60

Group type: COMPARATOR
Intervention: fentanyl group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: knee replacement
Number of subjects: 60
Study: 3544938

Group type: EXPERIMENTAL
Intervention: TTS-scopolamine (TTS-s)
Number of subjects: 59

Group type: COMPARATOR
Intervention: TTS-placebo (TTS-p)
Number of subjects: 59
Study: 31693541

Group type: EXPERIMENTAL
Intervention: GET Living (graded exposure treatment)
Number of subjects: 27
Study: 30183414

Group type: EXPERIMENTAL
Intervention: Clinician-facilitated physical activity intervention (PAI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 50
Study: 26386732

Group type: EXPERIMENTAL
Intervention: In-centre nocturnal hemodialysis (INHD)
Number of subjects: 67
Study: 24907643

Group type: EXPERIMENTAL
Intervention: PVI+CFAE group (n = 35)
Number of subjects: 68

Group type: COMPARATOR
Intervention: PVI-alone group (n = 33)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall (PVI-alone vs PVI+CFAE)
Number of subjects: 68
Study: 22573599

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) for 7 weeks
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 272
Study: 21981842

Group type: EXPERIMENTAL
Intervention: Combination therapy with rosuvastatin 20 mg and fenofibric acid 135 mg
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Rosuvastatin monotherapy (10, 20, or 40 mg)
Number of subjects: 2182

Group type: COMPARATOR
Intervention: Rosuvastatin 5, 10, 20, or 40 mg; fenofibric acid 135 mg
Number of subjects: 2182
Study: 19092614

Group type: EXPERIMENTAL
Intervention: OP-1 Putty
Number of subjects: 335

Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 335
Study: 16908870

Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Responsive Education and Prelinguistic Milieu Teaching (RPMT)
Number of subjects: 36
Study: 14666012

Group type: EXPERIMENTAL
Intervention: 200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control (n=10)
Number of subjects: 20
Study: 10705191

Group type: EXPERIMENTAL
Intervention: Fiuggi mineral water (oligomineral water with a calcium content of 15 mg/l)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Tap water (calcium content ranging between 55 and 130 mg/l)
Number of subjects: 384
Study: 9023787

Group type: EXPERIMENTAL
Intervention: Venlafaxine (375 mg/day for 10 days, then reduced to 150 mg/day)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Imipramine (200 mg/day)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 167

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 167
Study: 1670783

Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96
Study: 6182075

Group type: EXPERIMENTAL
Intervention: Thermal modalities and transcutaneous electrical nerve stimulation for pain control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulatory assistive devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Below the knee bearing braces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive and corrective footwear and shoe modification
Number of subjects: 0
Study: 30790557

Group type: EXPERIMENTAL
Intervention: HABIT-ILE (hand-arm bimanual intensive therapy) delivered over 2 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional therapy (mostly neurodevelopmental) delivered 1-5 times/week
Number of subjects: 41
Study: 28379310

Group type: EXPERIMENTAL
Intervention: E/A ratio increase (per 0.1 increase)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Left atrial volume increase (per 5 mL increase)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Left atrial area increase (per 5 cm2 increase)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Peak A wave velocity increase (per 10 cm/s increase)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Peak A wave velocity adjusted for left atrial volume
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Left atrial volume adjusted for peak A wave velocity
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Left atrial area adjusted for peak A wave velocity
Number of subjects: 573
Study: 26535967

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg bid)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Oxycodone CR (20-50 mg bid)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 210

Group type: COMPARATOR
Intervention: Oxycodone CR
Number of subjects: 210
Study: 23493606

Group type: EXPERIMENTAL
Intervention: EE 20 µg/DRSP 3 mg (flexible extended regimen)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: EE 20 µg/DRSP 3 mg (conventional 28-day cyclic regimen)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: EE 20 µg/DRSP 3 mg (fixed extended regimen)
Number of subjects: 1100
Study: 20875905

Group type: EXPERIMENTAL
Intervention: CFF to red stimuli in patients with optic neuritis related to multiple sclerosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CFF to blue stimuli in patients with diabetic retinopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFF values in healthy subjects
Number of subjects: 0
Study: 19436647

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) without thrombectomy
Number of subjects: 0
Study: 17420364

Group type: EXPERIMENTAL
Intervention: Topical beta-adrenergic antagonists
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues
Number of subjects: 727
Study: 15547470

Group type: EXPERIMENTAL
Intervention: Mydriasert insert
Number of subjects: 72

Group type: COMPARATOR
Intervention: Eye drops (active control)
Number of subjects: 72
Study: 12467106

Group type: EXPERIMENTAL
Intervention: 100 mg/kg glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: saccharin (placebo)
Number of subjects: 0
Study: 9117888

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 8
Study: 7892364

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 82
Study: 3025246

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic saline (NS) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRH administration during saline infusions
Number of subjects: 0
Study: 28476901

Group type: COMPARATOR
Intervention: Education on symptoms management and training modifications (education)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exercise programme in addition to education (exercises)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Gait retraining in addition to education (gait retraining)
Number of subjects: 69
Study: 28296588

Group type: EXPERIMENTAL
Intervention: AppleMetS® (AMS), 2 capsules a day for one month
Number of subjects: 0
Study: 26202924

Group type: EXPERIMENTAL
Intervention: G5 culture medium
Number of subjects: 20

Group type: COMPARATOR
Intervention: HTF culture medium
Number of subjects: 20
Study: 24015630

Group type: EXPERIMENTAL
Intervention: Adenoidal hypertrophy group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study: 21435021

Group type: EXPERIMENTAL
Intervention: 0.06% retinyl retinoate cream for 3 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0.075% retinol cream
Number of subjects: 11
Study: 18339027

Group type: EXPERIMENTAL
Intervention: QFT-G 'In Tube' assay
Number of subjects: 191

Group type: COMPARATOR
Intervention: TST
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: QFT-G 'In Tube' assay and TST
Number of subjects: 191
Study: 16887890

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of disulfiram and naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14612213

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 70
Study: 10809907

Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg kg‐1 12 h prior to surgery plus 5 microg kg‐1 0 h prior to surgery)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8608540

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HF) at doses of 64.8, 72, 76.8, or 81.6 Gy
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy (AHF) at doses of 48 or 54.4 Gy
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) administered with both HF and AHF
Number of subjects: 786
Study: 1447500

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6142716

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30806856

Group type: EXPERIMENTAL
Intervention: Flaxseed poultice compress
Number of subjects: 82

Group type: COMPARATOR
Intervention: Hot compress
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 82
Study: 27618639

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (homework‐focused parent training and a daily report card; BPT + DRC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75
Study: 26527162

Group type: EXPERIMENTAL
Intervention: Biodegradable magnesium screws and vascularized iliac grafting
Number of subjects: 19